New frontiers for ovarian cancer risk evaluation: Proteomics and contrast-enhanced ultrasound

American Journal of Roentgenology

Volumn 194, Issue 2, 2010, Pages 349-354

  Dutta, Sonia ^a   Wang, Feng Qiang ^a   Fleischer, Arthur C ^b   Fishman, David A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CA 125; Contrast enhanced ultrasound; Early detection; Ovarian cancer; Proteomics; Serum biomarkers

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

CANCER RISK; CANCER SCREENING; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH;

CA-125 ANTIGEN; CONTRAST MEDIA; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEOMICS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER;

EID: 76149126105     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3763     Document Type: Review

References (35)

1. Ozols RRS, Thomas GM, Robby SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, eds. Principles and practice of gynecologic oncology. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001:165-18 2
2. Fishman DA, Bozorgri K. The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCDEP). Cancer Treat Res 2002; 107:3-28
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
4. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early-stage epithelial ovarian carcinoma? Gynecol Oncol 2000; 77:347-349
5. Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of earlystage epithelial ovarian cancer. Am J Obstet Gynecol 2005; 192:1214-1221; discussion, 1221-1212
6. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001; 82:40-48
7. Cohen L, Fishman DA. Ultrasound and ovarian cancer. Cancer Treat Res 2002; 107:119-132
8. Rockhill B. Proteomic patterns in serum and identification of ovarian cancer. (letter) Lancet 2002; 360:169; author reply, 170-171
9. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005; 58:308-312
10. Gagnon A, Ye B. Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 2008; 20:9-13
11. Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3:2085-2090
12. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577
13. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411:375-379
14. Terracciano R, Gaspari M, Testa F, et al. Selective binding and enrichment for low-molecular-weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 2006; 6:3243-3250
15. Goodacre R, Heald JK, Kell DB. Characterisation of intact microorganisms using electrospray ionisation mass spectrometry. FEMS Microbiol Lett 2006; 176:17-24
16. Holland RD, Wilkes JG, Rafii F, et al. Rapid identi-fication of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1996; 10:1227-1232
17. Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest 2005; 23:36-46
18. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2:1096-1103
19. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. (abstr) Nature 2003; 425:905
20. Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005; 51:1933-1945
21. Fleischer AC, Wojcicki WE, Donnelly EF, et al. Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med 1999; 18:547-551
22. Donnelly EF, Geng L, Wojcicki WE, Fleischer AC, Hallahan DE. Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 2001; 219:166-170
23. Fleischer AC. Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications. J Ultrasound Med 2000; 19:55-61
24. Fleischer AC, Niermann KJ, Donnelly EF, et al. Sonographic depiction of microvessel perfusion: principles and potential. J Ultrasound Med 2004; 23:1499-1506
25. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000; 34:148-155
26. Leen E. Ultrasound contrast harmonic imaging of abdominal organs. Semin Ultrasound CT MR 2001; 22:11-24
27. Orden MR, Jurvelin JS, Kirkinen PP. Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 2003; 226:405-410
28. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000; 7:824-839
29. Hall GH, Atkin SL, Turnbull LW. Use of dynamic contrast-enhanced MRI to assess the functional vascular pharmacokinetic parameters of normal human ovaries. J Reprod Med 2002; 47:107-114
30. Huber S, Helbich T, Kettenbach J, Dock W, Zuna I, Delorme S. Effects of a microbubble contrast agent on breast tumors: computer-assisted quantitative assessment with color Doppler US-early experience. Radiology 1998; 208:485-489
31. Furlow B. Contrast-enhanced ultrasound. Radiol Technol 2009; 80[suppl]:547S-561S
32. Eckersley RJ, Sedelaar JP, Blomley MJ, et al. Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma. Prostate 2002; 51:256-267
33. Krix M, Kiessling F, Vosseler S, et al. Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography: quantification of tumour perfusion in small animals. Ultrasound Med Biol 2003; 29:1093-1103
34. Fleischer AC, Lyshchik A, Jones HW Jr, et al. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med 2008; 27:1011-1018; quiz, 1019-1021
35. Fleischer AC, Lyshchik A, Jones HW 3rd, et al. Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast-enhanced transvaginal sonography. J Ultrasound Med 2009; 28:1273-1280